Document:

Exhibit 4.11

EXECUTION VERSION

COLLABORATION
AGREEMENT

This Collaboration
Agreement is made and entered into as of April 30,  2001 by and among Chiron Behring GmbH & Co, a company incorporated in Germany,
with offices at Emil von Behring Strasse 76, 35041 Marburg, Germany (“Chiron Behring”), Chiron S.p.A., a company
incorporated in Italy, with offices at Via Fiorentina 1, 53100 Siena, Italy (“Chiron S.p.A.”, and together with Chiron
Behring GmbH & Co, “Chiron”),
Rhein Biotech N.V., a company incorporated in the Netherlands, with offices at
Gaetano Martinolaan 95, 6229 GS Maastricht, The Netherlands (“Rhein Biotech”), and GreenCross Vaccine
Corporation, a company incorporated in the Republic of Korea, with offices at
303 Bojung-Ri, Koosung-Eup, Yongin 449-770, Republic of Korea (“GCVC”, and together with Rhein Biotech, “Rhein Biotech and GCVC”).

RECITALS

A.   WHEREAS, Chiron and Rhein Biotech each has
developed expertise in the fields of vaccine research, development and
manufacturing.

B.   WHEREAS, Chiron and Rhein Biotech entered
into a Letter of Intent dated as of December 1, 2000 (the “Letter of
Intent”) with respect to their intent to co-develop and manufacture one or more
new pentavalent combination vaccines for pediatric use.

C.   WHEREAS, Chiron, Rhein Biotech and GCVC
entered into a Materials Transfer Agreement effective as of December 11,
2000 (the “Materials Transfer Agreement”) with respect to their respective
rights and obligations in connection with any materials transferred in
connection with the project contemplated by the Letter of Intent.

D.   WHEREAS, Chiron, Rhein Biotech and GCVC
wish to collaborate on the research, development, manufacturing and
commercialization of one or more new pentavalent combination vaccines for
pediatric use on the terms and conditions set forth herein with a view to
reducing duplicative, unnecessary costs, exchanging ideas and developing
resulting products and technologies more rapidly than would otherwise be the
case.

NOW
THEREFORE in consideration of the premises and other good and
valuable consideration, Chiron and Rhein Biotech and GCVC agree as follows.

 1
 

 

ARTICLE 2 

COLLABORATION

2.1                  Collaboration. Chiron,
Rhein Biotech and GCVC shall establish a collaboration in the Field (the “Collaboration”)
subject to the terms and conditions set forth in this Collaboration Agreement.
The Parties shall collaborate on research, development and commercialization of
the Whole Cell Product and, subject to the terms of Section 2.5, of the
Acellular Product, all as more fully set forth in this Collaboration Agreement

2.2                  Annual Plan and
Budget for 2001. Attached as Schedule I hereto is the Annual Plan and
Budget for the year 2001, which shall be deemed to have been approved by the
Parties.

2.3                  Level of Effort.
Each Party shall use commercially reasonable efforts to perform the duties and
obligations assigned to it under this Collaboration Agreement and the Annual
Plans and Budgets and shall employ at least the level of effort and care that
such Party would use in performing similar activities in connection with its
own internal projects with comparable risk/reward profiles.

2.4                  Commitment to
Annual Plan and Budget. Each Party shall use and shall cause its Affiliates
to use all reasonable efforts to conduct its activities in accordance with and
within the parameters set by the Annual Plan and Budget, including without
limitation, making all investment in the Collaboration necessary and in
accordance with the Investment Plan attached as Schedule L and the timelines
for the Collaboration set forth in each Annual Plan and Budget and the
Collaboration and Development Plan in order to meet the levels of production of
the Product set forth in each Annual Plan and Budget.

2.5                  Acellular
Product. The Parties agree that they shall collaborate exclusively for a period of twelve months from the
Effective Date to evaluate alternatives for implementation of the Collaboration
with respect to the Acellular Product. The provisions in the Collaboration and
Development Plan with respect to the Acellular Product shall be used as a basis
for such evaluation. If either Party, in its sole discretion, determines during
such twelve month evaluation that the Collaboration with respect to the
Acelluar Product should not proceed, such Party shall notify the other Party in
writing of such determination and the Collaboration with respect to the
Acellular Product shall be terminated with immediate effect. For the avoidance
of doubt, all R & D
Expenses incurred by either Party prior to any such termination of the
Collaboration with respect to the Acellular Product shall be shared by the
Parties in accordance with the terms of Section 6.2.

 2
 

 

(d)                   establish
annually the amount allocable to each FTE for each Party, including all
associated costs, such as salaries, benefits, lab materials and supplies,
non-capitalized equipment, depreciation, repair and maintenance and other
ordinary direct expenses related to research and development activities.

(e)                    consider
and determine whether and when to initiate clinical studies of the Product in
humans;

(f)                      consider
and determine whether it is necessary or appropriate for the Parties to obtain
access to intellectual property or technologies Controlled by Third Parties
and, if so, review and approve the terms of any proposed license or similar
agreement;

(g)                   consider
and determine whether it is appropriate to grant to Third Parties any licenses
or other rights with respect to Collaboration Technology;

(h)                   review
and approve the publication of any Collaboration Technology;

(i)                       consider
and determine a patent strategy for Collaboration Technology;

(j)                       in
general, to direct the research, development and commercialization of the
Product in accordance with the terms and conditions of this Collaboration
Agreement;

(k)                    consider
any decisions required to be taken pursuant to the terms of Schedule G to the
Bulk Supply Agreement and the Supply and Manufacturing Agreement; and

(1)                    review
on a regular basis the overall pricing policy applied by both Parties.

3.3                  Subcommittees.
The Steering Committee may from time to time establish, and delegate certain of
its responsibilities to, one or more subcommittees (including, without
limitation, a development committee, a scientific subcommittee, a finance
subcommittee, and a marketing subcommittee). Each such subcommittee shall be
comprised of an equal number of representatives from Chiron on the one hand and
Rhein Biotech and GCVC on the other hand. Either Party, in its sole discretion,
may from time to time remove one or more of its appointees from any such
subcommittee and appoint new members with appropriate expertise in their place.

3.4                  Meetings.
The Steering Committee shall meet at least once every six months, and each
standing subcommittee shall meet at least once each calendar quarter at
alternatively Rhein Biotech and GCVC’s and Chiron’s facilities or another
location mutually agreed upon by the members of such committee. These meetings
may be waived or held by telephone or videoconference if agreed by all

 3
 

 

activities conducted by third parties, such as clinical trials. All
manufacturing costs, such as the costs of producing clinical lots, incurred
prior to commercialization shall be shared by the Parties in accordance with
the terms of Section 6.2 and reimbursed on a period basis prior to
commercialization; and (iii) all other costs (other than capital costs but
including depreciation on such capital expenditures) shall be reimbursed on a
period basis. Each Party shall use all reasonable
efforts to include such costs in the Annual Plan and Budget. In no event shall
the Allowable Expenses for research and development exceed by 120% the Annual
Plan and Budget. Moreover, the Parties agree that the initial estimate of the
expected lifetime development costs of the Collaboration will be in the range
United States Dollars to United States Dollars, generally in accordance with
the terms of Schedule H, which amount shall not be exceeded by more than ten
percent (10%) without prior approval of the Steering Committee.

4.3                  Product
Registrations. Subject to the terms of Section 3.2 (Functions), each
Party shall prepare, file and control all IND’s and BLA’s in its respective
sales and marketing Territory. Each Party shall consult with, and provide all
reasonable assistance to the other with respect to such filings. Each Party
shall be permitted to attend all meetings with the Regulatory Agencies relating
to such filings. Each Party shall hold all Marketing Authorizations in its
respective sales and marketing Territory in its name on behalf of the
Collaboration, unless otherwise required by law.

4.4                  Manufacture of
R&D Supplies. Subject to the terms of Section 3.2 (Functions), the
manufacture of all supplies of the Product required for research and
development purposes shall be as provided for in the Collaboration and
Development Plan.

ARTICLE
5

COMMERCIALIZATION

5.1                  Marketing and
Sales. Subject to the terms of Section 6.4 (Commercialization), each
Party shall have exclusive rights to market and sell the Product on behalf of
the Parties in its respective sales and marketing Territory as follows:

(a)                    the
Rhein Biotech and GCVC territory shall be (i) with respect to the Whole
Cell Product, supranational institutions, such as WHO, PAHO, GAVI and UNICEF,
worldwide (the “Rhein Biotech and GCVC Whole Cell Product Territory”); and (ii) with
respect to the Acellular Product, if any, North Korea and South Korea (the “Rhein
Biotech and GCVC Acellular Product Territory”)(the Rhein Biotech and GCVC Whole
Cell Product Territory and the Rhein Biotech and GCVC Acellular Product
Territory herein jointly referred to as the “Rhein Biotech and GCVC Territory”);
and

(b)                   the
Chiron territory shall be (i) with respect to the Whole Cell Product, the
private

 4
 

 

costs of any such inspection.

5.5                  Contract Requirements. Chiron and Rhein Biotech and GCVC each shall
be obligated to provide the Chiron Materials and the Rhein Biotech and GCVC
Materials, respectively, in sufficient quantities to fulfill the Minimum Contract Requirements set forth in the Bulk
Supply Agreement and the Supply and Manufacturing Agreement.

ARTICLE
6

PAYMENTS

6.1                  Upfront Payments. Neither Party
shall be obligated to pay any upfront payments to the other Party.

6.2                  R&D Cost-sharing Prior to Commercialization.

(a)                    Rhein Biotech
and GCVC and Chiron shall share all R&D Expenses incurred in connection
their activities under this Collaboration Agreement as follows:

(i)                        Rhein
Biotech and GCVC shall pay and Chiron shall pay of the R&D Expenses
incurred on or after December 1, 2000 for the Collaboration with respect
to the Whole Cell Product; and

(ii)                     Rhein
Biotech and GCVC shall pay and Chiron shall pay of the R&D Expenses
incurred for the Collaboration with respect to the Acellular Product, if any.

(b)                   The agreed
accounting methodologies for determining R&D Expenses are included in
Schedule F to this Collaboration Agreement.

(c)                    The agreed
reporting requirements with respect to R&D Expenses are included in
Schedule F to this Collaboration Agreement. Within 15 days of receipt of such
reports, the Parties shall determine the sum of all R&D Expenses incurred
by both Parties, and a single payment shall be made by one Party to the other
Party such that total R&D Expenses are shared in accordance with paragraph
(a).

6.3                  Milestone Payments. Neither Party shall be
obligated to pay any milestone payments to the other Party.

 5
 

 

ARTICLE 7

INTELLECTUAL PROPERTY

7.1                  Ownership.

(a)                    Contributed Chiron Technology. All Contributed
Chiron Technology shall be owned solely and exclusively by Chiron. No licenses
are granted except as expressly set forth in Article 8 (Licenses) or Article 14
(Termination).

(b)                   Contributed Rhein Biotech and
GCVC Technology. All
Contributed Rhein Biotech and GCVC Technology shall be owned solely and
exclusively by Rhein Biotech and GCVC. No licenses are granted except as
expressly set forth in Article 8 (Licenses) or Article 14
(Termination).

(c)                    Chiron/Rhein Biotech and GCVC
Joint Background Technology. All
Chiron/Rhein Biotech and GCVC Joint Background Technology shall continue
to be owned jointly by Chiron and Rhein Biotech and GCVC. Except as otherwise expressly set
forth in Article 14 (Termination), neither Party shall license its
interest in Chiron/Rhein Biotech and GCVC Joint Background Technology without
the prior written consent of the other Party.

7.2                  Ownership of
Collaboration Technology.

(a)                    Ownership. All Collaboration Technology shall be jointly
owned by Rhein Biotech and GCVC and Chiron.

(b)                   Licenses. Except as otherwise expressly set forth in Article 14
(Termination), neither Party shall license its interest in Collaboration
Technology without the prior written consent of the other Party.

7.3                  Patent Filing,
Prosecution, Maintenance and Defense. Chiron shall file, prosecute,
maintain and defend the Collaboration Patents in accordance with the patent
strategy established by the Steering Committee. Chiron shall keep Rhein Biotech
and GCVC fully and promptly informed of the status of the prosecution of such
Collaboration Patents, shall consult with Rhein Biotech and GCVC concerning
each step of such prosecution, and shall afford Rhein Biotech and GCVC timely
opportunity to review and comment on any submission to be made in connection
therewith. Rhein Biotech and GCVC shall cooperate fully with Chiron in
connection with such matters. All costs and expenses incurred by either Party
in connection therewith shall be shared, with Chiron paying of such costs and
Rhein Biotech and GCVC paying thereof.

7.4                  Infringement
Action By A Third Party. Each Party shall promptly notify the other Party
in the event any legal proceedings are commenced or threatened against

 6
 

 

ARTICLE 8

LICENSES

8.1                  License to Contributed Chiron Technology. Subject to the
terms and conditions of this Collaboration Agreement, Chiron hereby grants to
Rhein Biotech and GCVC a worldwide royalty-free license, without the right to
sublicense, under the Contributed Chiron Technology, to make, use and sell the
Product. Such license shall be co-exclusive with Chiron.

8.2                  License to Contributed Rhein Biotech and GCVC Technology.
Subject to the terms and conditions of this Collaboration Agreement, Rhein
Biotech and GCVC hereby grants to Chiron a worldwide royalty-free license,
without the right to sublicense, under the Contributed Rhein Biotech and GCVC
Technology, to have made, use and sell the Product. Such license shall be
co-exclusive with Rhein Biotech and GCVC.

ARTICLE
9 

MATERIALS

9.1                  Rhein Biotech and GCVC Materials. Rhein Biotech and GCVC is
the sole and exclusive owner or licensee of the Rhein Biotech and GCVC
Materials. Chiron shall be permitted to use the Rhein Biotech and GCVC
Materials for purposes of the Collaboration and for no other purposes
whatsoever. Chiron shall have no rights or licenses to the Rhein Biotech and
GCVC Materials except as expressly set forth herein. Chiron shall not provide
any Rhein Biotech and GCVC Materials to any unaffiliated third party without
the prior written consent of Rhein Biotech and GCVC. Except as expressly set
forth herein or otherwise required by applicable law or regulations, upon the
termination of the Collaboration, Chiron shall cease to use the Rhein Biotech
and GCVC Materials and shall, at Rhein Biotech and GCVC’s option and expense,
either destroy the Rhein Biotech and GCVC Materials or return the Rhein Biotech
and GCVC Materials to Rhein Biotech and GCVC.

9.2                  Chiron Materials. Chiron is the sole and exclusive owner or
licensee of the Chiron Materials. Rhein Biotech and GCVC shall be permitted to
use the Chiron Materials for purposes of the Collaboration and for no other
purposes whatsoever. Rhein Biotech and GCVC shall have no rights or licenses to
the Chiron Materials except as expressly set forth herein. Rhein Biotech and
GCVC shall not provide any Chiron Materials to any unaffiliated third party
without the prior written consent of Chiron. Except as expressly set forth
herein or otherwise required by applicable law or regulations, upon the
termination of the Collaboration, Rhein Biotech and GCVC shall cease to use the
Chiron Materials and shall, at Chiron’s option and expense, either destroy the
Chiron Materials or return the Chiron Materials to Chiron.

 7
 

 

(a)                    is
or hereafter becomes generally available to the public other than by reason of
any breach or default by the Receiving Party of its confidentiality obligation
under this Collaboration Agreement;

(b)                   was
already known to the Receiving Party (as shown by its written records) prior to
the date of receipt by the Receiving Party from the Disclosing Party hereunder
or is independently developed by the Receiving Party (as shown by its written
records) without access to the Disclosing Party’s information; or

(c)                    is
disclosed to the Receiving Party by a third-party not directly or indirectly
under a duty of confidentiality to the Receiving Party;

(d)                   to
the extent such disclosure is reasonable necessary in connection with the
following:

(i)                        filing,
prosecuting or maintaining Collaboration Patents;

(ii)                     IND’s
or BLAs;

(iii)                  prosecuting or defending litigation;

(iv)                 compliance
with applicable laws or court orders.

Whenever the Receiving Party becomes aware of any state of facts which
would or might result in disclosure of Confidential Information pursuant to
subparagraph (d) above, it shall, if possible, promptly notify the Party
making disclosure (the “Disclosing Party”) prior to any such disclosure so that
the Disclosing Party may seek a protective order or other appropriate remedy
and/or waive compliance with the provisions of this Collaboration Agreement. In
any event, if the Receiving Party is unable to promptly notify the Disclosing
Party or if such protective order or other remedy is not obtained, or if the
Disclosing Party waives compliance with the provisions of this Collaboration
Agreement, the Receiving Party will furnish only that portion of the
information which it is advised by counsel is legally required and will
exercise reasonable efforts to obtain assurance that confidential treatment
will be accorded the Confidential Information.

Each party shall be entitled, in addition to any other right or remedy
it may have, at law or in equity, to an injunction, enjoining or restraining
any other party from any violation or threatened violation of this Article 9.

10.3           Return of Confidential
Information. Within thirty (30) days after expiration or earlier
termination of this Collaboration Agreement, the Receiving Party shall (and
shall cause its Affiliates and their respective Representatives to) return to
the Disclosing Party or destroy all documents and tangible items (including
electronic format) then in its possession which contain, relate to or refer to
Confidential Information received from the Disclosing Party; provided, however,
that the Receiving Party may retain one copy of each document in its legal
files solely to permit the Receiving Party to comply with its obligations
hereunder.

 8
 

 

S.p.A. of its obligations hereunder have been duly authorized by all
necessary corporate action on the part of each of Chiron Behring and Chiron
S.p.A.;

(b)                   no
consent, license, permit, approval, order or authorization of, or registration,
declaration, qualification or filing with, any foreign, federal, state,
provincial or local governmental authority is required to be obtained or made
in connection with the execution and delivery of this Collaboration Agreement
by Chiron Behring or Chiron S.p.A. or the performance of its obligations
hereunder;

(c)                    the
execution and delivery by each of Chiron Behring and Chiron S.p.A. of this
Collaboration Agreement and the performance by each of Chiron Behring and
Chiron S.p.A. of its obligations hereunder do not conflict with or require the
consent of any third party to any contract, agreement, commitment, covenant,
understanding or arrangement to which Chiron Behring or Chiron S.p.A. is a
party;

(e)                    Chiron
owns or controls the Contributed Chiron Technology free and clear of any liens,
claims, encumbrances or charges, and has not previously licensed, assigned or
otherwise encumbered its right, title or interest in the Contributed Chiron
Technology in the Field.

EACH OF CHIRON BEHRING AND CHIRON S.P.A. DISCLAIMS ALL WARRANTIES,
EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, WARRANTIES OF
MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF THE ANY AND ALL
PRODUCTS OR CHIRON MATERIALS SUPPLIED HEREUNDER, EXCEPT AS EXPRESSLY SET FORTH
IN THIS AGREEMENT.

12.2           Representations and
Warranties by Rhein Biotech and GCVC. Each of Rhein Biotech and GCVC
represents and warrants with respect to itself to Chiron, as of the Effective
Date, that:

(a)                    Each
of Rhein Biotech and GCVC is a corporation and is validly existing and in good
standing under the laws of its jurisdiction of incorporation; each of Rhein
Biotech and GCVC has all necessary corporate power to execute, deliver and
perform this Collaboration Agreement and to carry out its obligations hereunder
this Collaboration Agreement; and the execution and delivery of this
Collaboration Agreement by each of Rhein Biotech and GCVC and the performance
by each of Rhein Biotech and GCVC of its obligations hereunder have been duly
authorized by all necessary corporate action on the part of each of Rhein
Biotech and GCVC;

(b)                   no consent,
license, permit, approval, order or authorization of, or

 9
 

 

indemnification is sought (the “Indemnifying Party”) in writing
promptly upon becoming aware of any claim, threatened claim, damage, loss,
suit, proceeding or liability (“Claim”) to which such indemnification may
apply. Failure to provide such notice shall constitute a waiver of the
Indemnifying Party’s indemnity obligations hereunder if and to the extent the
Indemnifying Party is materially damaged thereby. The Indemnifying Party shall
have the right to assume and control the defense of the Claim at its own
expense. If the right to assume and control the defense is exercised, the
Indemnified Party shall have the right to participate in, but not control, such
defense at its own expense and the Indemnify Party’s indemnity obligations
shall be deemed not to include attorneys’ fees and litigation expenses incurred
by the Indemnified Party after the assumption of the defense by the
Indemnifying Party. If the Indemnifying Party does not assume the defense of
the Claim, the Indemnified Party may defend the Claim; provided, that the
Indemnified Party will not settle or compromise the Claim without consent of
Indemnifying Party, which consent will not be unreasonably withheld. The
Indemnified Party shall cooperate with Indemnifying Party and will make
available to Indemnifying Party all pertinent information under the control of
the Indemnified Party.

13.4           Waiver of Consequential or Punitive Damages.
Subject only to the terms of Section 14.6, no Party shall be liable to any
other Party for any special, incidental or consequential damages, including
lost profits, whether any claim for such recovery is based upon theories of
contract, negligence, or tort (including strict liability). Each Party hereby
waives for itself and its successors and assigns any and all claims for any
special, incidental or consequential damages, including lost profits.

13.5           Insurance. Each Party shall obtain and
maintain comprehensive general liability insurance, including product liability
insurance, with a reputable and financially secure insurance carrier(s), to
cover its activities under this Collaboration Agreement.

ARTICLE
14 

TERM, TERMINATION AND REMEDY FOR BREACH

14.1           Term. This Collaboration Agreement is
effective as of the date hereof and shall continue indefinitely unless
terminated by either Party in accordance with the terms hereof.

14.2           Mutual Agreement. The Parties may terminate
the Collaboration and the Collaboration Documents at any time by mutual written
agreement.

14.3           Termination for
Material Breach. Subject to the terms of this Section 14.3, either
Party may terminate the Collaboration and the Collaboration Documents by notice
with immediate effect in the event of the occurrence of a Material Breach

 10
 

 

Collaboration and the Collaboration Documents subject to receipt by the
Changed Party of written notice of the exercise of such right within ninety
(90) days after the completion of such acquisition.

14.5           Effect of Termination In General. Upon
termination of the Collaboration and the Collaboration Documents:

(a)                    each
Party shall be obligated to pay 50% of the Residual Expenses; and

(b)                   neither
Party shall be relieved of any obligation which accrued prior to the effective
date of such termination; in particular, each Party shall remain obligated to
pay its share of all R&D Expenses incurred by the Parties prior to
termination in accordance with the provisions of Section 6.2 and both
Parties shall fulfill all payment and other obligations incurred with respect
to commercialization of the Product prior to the date of such termination in
accordance with the provisions of Section 6.4.

(c)                    except
as provided in Section 14.3, Rhein Biotech and GCVC shall not have any
continuing license to or any other right, title or interest in or to the
Contributed Chiron Technology, and Chiron shall not have any continuing license
to or any other right, title or interest in or to the Contributed Rhein Biotech
and GCVC Technology;

(d)                   the
Parties shall continue to jointly own all Collaboration Technology developed
prior to such termination; each Party shall have the right to freely license
its interest in such Collaboration Technology without the consent of the other
Party; and neither Party shall be obligated to pay any royalties to the other
Party for the use of such Collaboration Technology by such Party or its
licensees;

(e)                    The
following provisions shall survive any such termination. Article 6
(Payments), Article 7 (Intellectual Property), Article 8 (Licenses), Article 10
(Confidentiality), Article 12 (Representations and Warranties), Article 13
(Indemnification and Insurance) and Article 14 (Termination).

14.6           Remedies for Other Breaches. The Parties
agree that the remedies set forth below shall be the exclusive remedies with
respect to the following other breaches under the Collaboration Documents:

(a)                    In
the event (i) either Party shall breach Section 5.5 (Contract
Requirements) or (ii) there is a delay in the supply of any Materials
other than by reason of Force Majeure or by reason of any processing failure
beyond the reasonable control of the relevant Party by more than thirty (30)
days, the Party in breach or with respect to whose Materials such delay has
occurred shall pay to the other Party one percent(l%) of the then minimum
selling price of the Product per day as a penalty.

 11

 

 

If to Rhein Biotech and
GCVC:

GreenCross Vaccine
Corporation 

303 Bojung-Ri, Koosung-Eup 

Yongin 449-770 

Republic of Korea

Attention: Representative
Director 

Facsimile: 82 31 260 9012

with a copy to:

Rhein Biotech N.V. 

Gaetano Martinolaan 95 

6229 GS Maastricht 

The Netherlands

Attention: CEO 

Facsimile: 31 43 35 67 899

15.2           Entire
Agreement. The
Collaboration Documents constitute the entire agreement between the Parties
hereto with respect to the subject matter hereof and supersede any prior
agreement whether written or oral.

15.3           Force
Majeure. Neither Party shall be held liable or responsible to the
other Party nor be deemed to have defaulted under or breached the Agreement for
failure or delay in fulfilling or performing any term of the Agreement when
such failure or delay is caused by or results from causes beyond the reasonable
control of the affected Party (including but not limited to fire, floods,
embargoes, war, acts of war (whether war be declared or not), insurrections,
riots, civil commotion, strikes, lockouts or other labor disturbances, acts of
God or acts, omissions or delays in acting by any governmental authority or the
other Party (collectively, “Events of Force Majeure”); provided, however, that
the affected Party (i) shall immediately notify the other Party of the
occurrence of any such Event of Force Majeure and (ii) shall exert all
reasonable efforts to eliminate, cure or overcome any such Event of Force
Majeure and to resume performance of its covenants with all possible speed; and
provided, further, that nothing contained herein shall require any Party to
settle on terms unsatisfactory to such Party any strike, lockout or other labor
difficulty, any investigation or proceeding by any governmental authority or
any litigation by any third-party. Notwithstanding the foregoing, to the extent
that an Event of Force Majeure continues for a period in excess of six (6) months,
the affected Party shall promptly notify in writing the other Party of such
Event of Force Majeure and within four (4) months of the other Party’s
receipt of such notice, the Parties agree to negotiate in good faith either (i) to
resolve the Event of Force Majeure, if possible, (ii) to extend by mutual
agreement the time period to resolve, eliminate, cure or overcome such Event of

 12
 

 

 

15.10    Absence of Existing
Competition. Each of Rhein Biotech and GCVC represents and warrants
to Chiron that, to the best of its knowledge and belief, neither of Rhein
Biotech or GCVC nor any Affiliate of either Rhein Biotech or GCVC is presently
engaged in the business of manufacturing, marketing or distributing the
Product. Chiron represents and warrants to Rhein Biotech and GCVC that, to the
best of its knowledge and belief, neither Chiron nor any Affiliate of Chiron is
presently engaged in the business of manufacturing, marketing or distributing
the Product.

15.11    Absence of
Future Competition. Except as otherwise provided in this
Collaboration Agreement, each Party covenants and agrees that none of such
Party or any Affiliate of such Party (whether or not such Affiliate has
accepted a sublicense hereunder and agreed to be bound by the terms hereof) or
any of their respective successors in interest shall engage in the business of
developing, manufacturing, marketing or distributing any Product in the Field
other than through Chiron and Rhein Biotech and GCVC, as contemplated by this
Collaboration Agreement, provided, however, that in the event the Collaboration
with respect to the Acellular Product is terminated pursuant to the terms of Section 2.5,
then this Section 15.11 shall not apply to any acellular product in the
Field.

15.12    Ethical
Business Practices. Neither Party, nor any person employed by it or
representing it, has ever made, offered, provided or authorized, and covenants
that neither it, nor any person employed by it or representing it, will make
offer provide or authorize, direct or indirectly, any payment or transfer of
anything of value to any official, representative or employee of any government
agency or instrumentality, any political party or officer thereof, or any
candidate for public office for the purpose of influencing a decision by any of
them in their official capacity, and no officer, director, partner, owner,
principal, employee, or agent of either Party is an official or employee of a
governmental agency or instrumentality or a government owned company in a
position to influence action or a decision regarding the activities of such
Party contemplated in this Collaboration Agreement. Each Party covenants that
it will inform the other, if and as soon as any person assumes such a position
as an official or employee of a governmental agency or instrumentality or
government owned company, while at the same time remaining an officer,
director, partner, owner, principal, employee, or agent of such Party.

15.13    Use of Name.
No right, express or implied, is granted to either Party by this Collaboration
Agreement to use in any manner any trademark or trade name of the other Party
including the names “Rhein Biotech and GCVC” and “Chiron” without the prior
written consent of the owning Party.

 13
 

 

 

IN WITNESS
WHEREOF, the parties have executed this Collaboration Agreement as of the date
set forth above.

	
  CHIRON BEHRING GMBH & CO

  	
   

  	
   

  	
   

  	
  RHEIN BIOTECH N.V.

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  By:

  	
   

  	
  /s/ John A. Lambert

  	
   

  	
   

  	
   

  	
  By:

  	
   

  	
  /s/ Jan Thio

  
	
  Name:

  	
   

  	
  John A. Lambert

  	
   

  	
   

  	
   

  	
  Name:

  	
   

  	
  Jan Thio

  
	
  Title:

  	
   

  	
  President, Chiron Vaccines

  	
   

  	
   

  	
   

  	
  Title:

  	
   

  	
  Business Director

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  CHIRON S.P.A.

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  By:

  	
   

  	
  /s/ Kees Moonen

  
	
  By:

  	
   

  	
  /s/ John A. Lambert

  	
   

  	
   

  	
   

  	
  Name:

  	
   

  	
  Kees Moonen

  
	
  Name:

  	
   

  	
  John A. Lambert

  	
   

  	
   

  	
   

  	
  Title:

  	
   

  	
  Legal Counsel

  
	
  Title:

  	
   

  	
  President, Chiron Vaccines

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  GREENCROSS VACCINE CORPORATION

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  By:

  	
   

  	
  /s/ Ton Kuiper

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Name:

  	
   

  	
  Ton Kuiper

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Title:

  	
   

  	
  Representative Director

  
											

 

 14
 

 

 

SCHEDULE A

DEFINITIONS

For the purposes of the
Collaboration Documents the following words and phrases shall have the
following meanings:

1.1                  INTENTIONALLY
DELETED

1.2                  “Affiliate”, with respect to any person,
means any company, entity, joint venture or similar business arrangement which
is controlled by, controlling or under common control with such person, and
shall include without limitation any company fifty percent or more of whose
voting stock or participating profit interest is owned or controlled, directly
or indirectly, by such person, and any company which owns or controls, directly
or indirectly, fifty percent or more of such person.

1.3                  “Allowable Expenses” means the fully
burdened, fairly allocated direct and indirect costs and expenses incurred by
either Party in connection with its activities under the Collaboration
Documents, which shall include a reasonable depreciation of employed assets, as
determined in accordance with the accounting methodologies set forth in
Schedule F to the Collaboration Agreement; provided that such costs and
expenses are contemplated by an Annual Plan and Budget approved in accordance
with the provisions of Article 3 of the Collaboration Agreement; provided,
however, that any depreciation and amortization associated with any capital expenditure
prior to commercialization of the Product shall be treated as an Allowable
Expense only to the extent that such expenses combined with the other R &
D Expenses do not exceed 120 % of the amount set forth in the Annual Plan and
Budget for R & D Expenses. Allowable Expenses shall not include any (a) Excluded
Expenses or (b) any allocation of general and administration expenses or
any G& A Markup or (c) any Sales & Marketing Expenses.

1.4                  “Annual Plan and Budget” means, with
respect to any year, a plan for such year which shall include at least the
following: planned research and development activities, including timeline and
targeted milestones; planned manufacturing activities; and planned sales and
marketing activities and which shall be prepared and approved in accordance
with the terms of Section 3.2(a) to the Collaboration Agreement.

1.5                  “Batch”
shall mean a specific quantity of the Product comprising a number of units
mutually agreed upon between Chiron and Rhein Biotech and GCVC, and that (a) is
intended to have uniform character and quality within specified limits,

 15
 

 

 

1.15           “Chiron Purchase Order” means written orders from Chiron to Rhein
Biotech and GCVC which shall specify (a) the quantity of the Product
ordered, (b) shipping instructions, (c) delivery dates, and (d) delivery
destinations.

1.16           “Chiron Purchase Price” means the price to be paid by Chiron to Rhein
Biotech and GCVC for the Product in accordance with the terms of Section 5.2 of the Supply and
Manufacturing Agreement.

1.17           “Chiron/Rhein Biotech and
GCVC Joint Background Technology” means

(a)                    all
inventions, discoveries, procedures, processes, methods, data, information,
results, trade secrets and know-how, whether patentable or otherwise, arising
out of the Materials Transfer Agreement prior to the Effective Date; and

(b)                   all
patents and patent applications claiming such inventions and other technology;
all patents issued from such patent applications; and all reissues,
confirmations, renewals, extensions, counterparts, divisions, continuations,
continuations-in-part, supplemental protection certificates or utility models
relating to such patents and patent applications.

1.17           “Chiron Territory” shall have the meaning
ascribed to it in Section 5.1(b) of the Collaboration Agreement.

1.18           “COGS” stands for cost of goods sold and
shall have the meaning ascribed to it in Schedule F to the Collaboration
Agreement.

1.19           “Collaboration” shall have the meaning
ascribed to it in Section 2.1 of the Collaboration Agreement.

1.20           “Collaboration Agreement” means the
collaboration agreement dated as of April 30, 2001 between Chiron and
Rhein Biotech and GCVC and all schedules, amendments and supplements thereto.

1.21           “Collaboration and Development Plan” means
the collaboration and development plan attached as Schedule H to the
Collaboration Agreement.

1.22           “Collaboration Documents” means the
Collaboration Agreement, the Bulk Supply Agreement and the Supply and
Manufacturing Agreement.

1.23           “Collaboration Inventions” shall have the
meaning ascribed to it in the definition of Collaboration Technology.

1.24           “Collaboration Know-How”
shall have the meaning ascribed to it in the definition of Collaboration
Technology.

 16
 

 

 

(b)                   all unpublished scientific, engineering,
economic, commercial and other technical data or information, research results, methods, processes,
procedures, trade-secrets and know-how relating to the Product which are
Controlled by Chiron as of the Effective Date.

1.27                       “Contributed Rhein Biotech and GCVC Technology” means:

(a)                    all patents and patent applications Controlled
by Rhein Biotech and GCVC as of the Effective Date that cover the Product,
including without limitation, the patents and patent applications listed on
Schedule C to the Collaboration Agreement; for these purposes a patent or patent
application shall be deemed to “cover”
the Product if the manufacture, use or sale of the Product by Chiron would
infringe a claim in such patent or patent application but for the licenses
contemplated hereby; all patents issued from such patent applications; and all
reissues, confirmations, renewals, extensions, counterparts, divisions,
continuations, continuations-in-part, supplemental protection certificates or
utility models relating to such patents and patent applications; and

(b)                   all unpublished scientific, engineering,
economic, commercial and other technical data or information, research results,
methods, processes, procedures, trade-secrets and know-how relating to the Product which are Controlled by Rhein Biotech and
GCVC as of the Effective Date.

1.28                       “Controls” or “Controlled” means possession of the right to grant
licenses or sublicenses without violating the terms of any agreement or other arrangement with, or the rights of, any Third Party.

1.29                       “Current Good Manufacturing Practices” or “cGMP” means the good manufacturing practices
required by each applicable regulatory authority at any time during the term of
this Agreement for the manufacture and testing of pharmaceutical materials as
applied solely to the Product.

1.30                       “Effective Date” means the date of the Collaboration Agreement.

1.31                       “Excluded
Expenses” means any and all costs and expenses incurred in defending,
settling or otherwise discharging any liability to a third party, including,
without limitation, any employee of either Party or their Affiliates, based
upon tortious acts.

 17
 

 

 

1.43           “Master Batch Record”
means, with respect to each Product to be Manufactured hereunder, a formal set
of instructions for the Manufacture of such Product.

1.44           “Material Breach” shall have the meaning ascribed
to it in Section 14.3 of the Collaboration Agreement.

1.45           “Minimum Contract
Requirements” means the quantity of the Product set forth in Schedule B to
the Bulk Supply Agreement and Schedule B to the Manufacturing and Supply
Agreement.

1.46           “Net Sales” means,
with respect to either Party, the total gross sales or consideration for the
Product charged to unaffiliated third parties, including without limitation,
amounts invoiced for sales of the Product, less the Sales and Return
Allowances, provided, however, that the selling Party may, at its option,
allocate the Sales and Return Allowances based upon accruals estimated
reasonably and consistent with such Party’s standard business practices; and
provided further, however, that if the selling Party elects to utilize such
accruals, actual deductions will be calculated and, if applicable, a “true-up”
made, on an annual basis and to the extent the aggregate amount of such
deductions is required under the terms of this Agreement to be allocated
between countries, such allocation will be in the same proportion as gross
sales of the Product realized in each country in the applicable period.

1.47           “Other Revenues” means
any revenues arising out of Collaboration Technology other than Net Sales,
including, without limitation, royalties or other amounts paid by Third Parties
for licenses to Collaboration Technology.

1.48           “Parties” means
Chiron and Rhein Biotech and GCVC and “Party” shall mean one of them.

1.49           “Product” means (a) the
Whole Cell Product; and (b) to the extent of the Collaboration proceeding
in accordance with the terms of Section 2.5 of the Collaboration
Agreement, the Acellular Product.

1.50           “Product Addendum”
means the addendum attached as Schedule C to the Bulk Supply Agreement and as
Schedule C to the Manufacturing and
Supply Agreement setting forth the Product Requirements, terms and
presentations for each Product Manufactured under the Bulk Supply Agreement and the Manufacturing and Supply
Agreement.

1.51           “Product Loss Allowance”
means the allowances for losses of the finished Product as more specifically
set forth in Schedule F to the Bulk Supply Agreement and the Supply and
Manufacturing Agreement.

1.52           “Product Requirements”
means the Product Specifications, the Master Batch Record and Rhein Biotech and
GCVC’s SOPs.

 18
 

 

 

substances (other than Chiron Materials, which combination shall be
deemed Collaboration Materials).

1.61           “Rhein Biotech and GCVC
Purchase Order” means written orders from Rhein Biotech and GCVC to Chiron
which shall specify (a) the quantity of the Bulk Chiron Material ordered, (b) shipping
instructions, (c) delivery dates, and (d) delivery destinations.

1.62           “Rhein Biotech and GCVC
Purchase Price” means the price to be paid by Rhein Biotech and GCVC to
Chiron for the Bulk Chiron Material in accordance with the terms of Section 3.2
of the Bulk Supply Agreement.

1.63           “Rhein Biotech and GCVC
Territory” shall have the meaning ascribed to it in Section 5.1 of the
Collaboration Agreement.

1.64           “Sales &
Marketing Expenses” means the following sales and marketing expenses for
the Product including:

(i)                       Costs
associated with sales representatives such as compensation, benefits, travel,
supervision and training of sales representatives, sales meetings and other
sales expenses.

(ii)                    Direct
costs of marketing, promotion, advertising, professional education, product
related to public relations, relationships with opinion leaders and
professional societies, market research and other similar activities.

1.65           “Sales and Return Allowances” means the following
sales and return allowances as determined under US GAAP:

(a)                    normal
and customary trade and/or quantity discounts;

(b)                   returns,
rebates, credit for product defects actually;

(c)                    to
the extent separately stated on purchase orders and invoices or other documents
of sale and actually taken:

(i)                        imported
and export duties;

(ii)                     excise,
sales or use taxes;

(iii)                  value added taxes, and other
governmental charges; and

(d)                   transportation,
transit and insurance for transportation, each to the extent separately
invoiced and paid by the selling Party.

1.66           “SOPS” mean standard operating procedures for
the Manufacture of the Product which shall be reviewed by both Parties.

1.67           “Steering Committee” shall have the meaning
ascribed to it in Article 3 of the Collaboration Agreement.

1.68           “Supply and Manufacturing Agreement” means
the supply and manufacturing agreement dated as of the date of the
Collaboration Agreement between Chiron and Rhein Biotech and GCVC, and all
schedules, amendments and supplements

 19EXHIBIT 4.12

Project: GMP Facility

Crucell
Holland B.V.

Date: August 27,
2005

Turn
Key Contract

between

Crucell Holland B.V.

Archimedesweg 4

NL - 2301 CA Leiden

The Netherlands

hereinafter referred to
as “Purchaser”

and

Pharmaplan
International GmbH

Borkenberg 14

D — 61440 Oberursel

Germany

hereinafter referred to
as “Seller”

 

CONTENTS

	
  1.

  	
  Preamble

  	
  3

  
	
  2.

  	
  Definitions

  	
  3

  
	
  3.

  	
  Subject of Contract

  	
  5

  
	
  4.

  	
  Seller’s Obligation

  	
  5

  
	
  5.

  	
  Purchaser’s Obligation

  	
  6

  
	
  6.

  	
  Schedule of Work, Time of Deliveries, Liquidated
  Damages

  	
  7

  
	
  7.

  	
  Representatives, Work on Site

  	
  8

  
	
  8.

  	
  Variations

  	
  10

  
	
  9.

  	
  Contract Price, Terms of Payment

  	
  11

  
	
  10.

  	
  Packing and Shipment

  	
  12

  
	
  11.

  	
  Inspections and Mechanical Completion

  	
  12

  
	
  12.

  	
  Passing of Risk, Liability, Insurance

  	
  13

  
	
  13.

  	
  Defects, Warranty

  	
  14

  
	
  14.

  	
  Safety Standards

  	
  15

  
	
  15.

  	
  Termination

  	
  16

  
	
  16.

  	
  Intellectual Property Rights

  	
  18

  
	
  17.

  	
  Confidentiality

  	
  18

  
	
  18.

  	
  Force Majeure

  	
  19

  
	
  19.

  	
  Limitation of Liability

  	
  19

  
	
  20.

  	
  Notices and Language

  	
  20

  
	
  21.

  	
  Arbitration, Applicable Law

  	
  20

  
	
  22.

  	
  Miscellaneous

  	
  20

  
	
  23.

  	
  Appendices

  	
  23

  

 

 2
 

 

 

	
  

  	
   

  	
  1. Preamble

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  Whereas the Purchaser intends to install a new GMP
  facility for the production of BSL-3/2-Vaccines (hereinafter
  referred to as the “Plant”) at his premises at Leiden (hereinafter referred
  to as the “Site”), and whereas Purchaser and Seller have negotiated and
  agreed to the implementation of such
  Plant, the parties, intending to be legally bound, hereby agree as follows:

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  2. Definitions

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  When used in this Agreement, the capitalized terms
  listed below shall have the following
  meanings:

  
	
   

  	
   

  	
   

  
	
  Commencement
  Date

  	
   

  	
  2.1. “Commencement Date” shall mean the date as
  specified in Sub -Clause 22.12 as the date for the commencement of the
  Contract.

  
	
   

  	
   

  	
   

  
	
  Contract

  	
   

  	
  2.2. “Contract” shall mean this
  Contract entered into between the Purchaser and the Seller, including
  all Appendices hereto, which form an integral part hereof as the same, and
  amendments of and additions to this document agreed in writing.

  
	
   

  	
   

  	
   

  
	
  Contract
  Price

  	
   

  	
  2.3. “Contract Price”
  shall mean the total amount to be paid by the Purchaser for the Work, excluding value added tax and all other taxes or duties levied in the country where the Site
  is located.

  
	
   

  	
   

  	
   

  
	
  Plant

  	
   

  	
  2.4. “Plant” shall mean
  a new GMP Facility for the production of BSL- 3/2-Vaccines

  
	
   

  	
   

  	
   

  
	
  Force
  Majeure

  	
   

  	
  2.5. “Force Majeure” shall have the meaning defined
  in Clause 18.

  
	
   

  	
   

  	
   

  
	
  Laws,
  Regulations and Standards

  	
   

  	
  2.6. “Laws, Regulations
  and Standards” shall mean any mandatory public
  regulation affecting the performance of the Contract, including official standards and norms, which according to
  such public regulations shall be applied.

  
	
   

  	
   

  	
   

  
	
  Schedule
  of Work

  	
   

  	
  2.7. “Schedule of Work”
  shall mean the document appended to the Contract
  which specifies the timing of major stages of the execution of the Scope of
  Supplies, as per Appendix 3.

  
	
   

  	
   

  	
   

  
	
  Project
  Manager

  	
   

  	
  2.08. “Project Manager”
  shall be the representative of either party who, until the end of the defects liability period under Clause 7, shall be
  authorised to make decisions on behalf
  of that party regarding all measures
  necessary for the performance of the Contract, including amendments and additions thereto.

  

 

 3
 

 

 

	
  Excusable Delays

  	
   

  	
  2.09. “Excusable Delays” - shall mean the
  following risks: 

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
  a) war and hostilities (whether war be declared or
  not), invasion, act of foreign enemies, 

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
  b) civil war, rebellion, revolution, insurrection,
  military or usurped power, riot, civil commotion or disorder, insofar as it
  relates to the country where the Site is located or countries through which
  supplies must be transported, 

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
  c) terrorist action or others acting from a
  political motive, 

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
  d) ionising radiation or contamination by
  radio-activity from any nuclear fuel or nuclear weapons material, or from any
  nuclear waste from the combustion of nuclear fuel, radio-active toxic
  explosives or other hazardous properties of any explosive nuclear assembly or
  nuclear components thereof,

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
  e) confiscation, commandeering, requisition or
  destruction of or damage to property by order of the government or by any
  public authority, 

  
	
   

  	
   

  	
   

  	
   

  
	
  

  	
   

  	
   

  	
  f) pressure waves caused by aircraft travelling at
  sonic or supersonic speed.

  
	
   

  	
   

  	
   

  
	
  Ruling
  Language

  	
   

  	
  2.10. “Ruling Language” - shall have the
  meaning defined in Sub-Clause 20.

  
	
   

  	
   

  	
   

  
	
  Site

  	
   

  	
  2.11. “Site” shall mean the place where the Plant is
  to be erected, including adjacent areas necessary for unloading, storage and
  internal transport of products, materials and equipment.

  
	
   

  	
   

  	
   

  
	
  Site
  Representative

  	
   

  	
  2.12. “Site Representative” shall be the
  representative of either party who, from the start of the Seller’s execution
  of the Scope of Supply on Site until the same have been taken over and shall
  be authorised to make decisions on behalf of that party concerning the day to
  day management of operations relating to the execution of the Scope of Supply
  on Site, and have such further powers as are assigned to him/her by such
  party and notified to the other party. The Site Representative can be either
  the Project Manager or somebody to be announced in writing six (6) weeks
  prior to start with major activities on Site.

  
	
   

  	
   

  	
   

  
	
  Subcontractor

  	
   

  	
  2.13. “Subcontractor” shall mean any firm or person
  to whom execution of any part of the Scope of Supply, including design and
  supply of materials, is directly or indirectly subcontracted by Seller,
  including such persons’ legal successors and permitted assigns. The Contract
  engaging a Subcontractor is referred to as a “Subcontract”.

  
	
   

  	
   

  	
   

  
	
  Mechanical
  Completion

  	
   

  	
  2.14. “Mechanical Completion” shall mean that the
  Scope of Supply has been performed and the Plant is structurally and
  electrically completed and in a functional, clean condition, that all the
  equipment has been installed and is ready for Installation Qualification (IQ).

  

 4

 

	
  Time for Completion

  	
   

  	
  2.15. “Time for Completion” shall mean the time
  within which, according to the Contract, the Scope of Supply shall be
  completed in accordance with the Contract and shall be taken over by the
  Purchaser, where applicable as extended in accordance with the Contract.

  
	
   

  	
   

  	
   

  
	
  Scope
  of Supply

  	
   

  	
  2.16. “Scope of Supply” shall mean all supplies and
  services, as specified in detail with Appendix 1, to be provided by Seller
  pursuant to the Contract, including variations in accordance with Clause 8.
  Supplies, equipment and services which, according to the Contract, shall not
  be provided by Seller, but by the Purchaser or a third party employed by the
  Purchaser shall not be deemed part of the Scope of Supply.

  
	
   

  	
   

  	
   

  
	
  Incoterms
  2000

  	
   

  	
  2.17. “Incoterms 2000” shall mean the set of
  international trade terms and rules published by the International
  Chamber of Commerce.

  
	
   

  	
   

  	
   

  
	
  Basic
  Engineering Package

  	
   

  	
  2.18. “Basic Engineering Package” shall mean the set
  of documentation (as per Appendix 9) submitted by Seller in August 2005
  and approved by Purchaser.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  3. Subject of
  Contract

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  The Subject of this Contract is the design, delivery
  and erection of machinery, equipment and prefabricated modules for the Plant
  by Seller according to the Basic Engineering Package (Appendix 9) and the
  technical specifications attached to this Contract (Appendix 1). The Scope of
  the Contract also includes the incorporation of Purchaser’s supplies into the
  Plant as described more specifically with Appendix 1.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  4. Seller’s Obligations

  
	
   

  	
   

  	
   

  
	
  Seller’s
  General Obligations

  	
   

  	
  4.1. The Seller shall, in accordance with the
  Contract, with due care and diligence carry out the Scope of Supply within
  the time limit(s) specified in the Schedule of Work, where applicable as
  extended in accordance with the Contract, and perform such other obligations
  as are specified in the Contract. The Seller shall, unless otherwise
  specified in the Contract, be responsible for design, manufacture or
  procurement, testing and commissioning of all parts of the Scope of Supply as
  prescribed in the Contract.

  
	
   

  	
   

  	
   

  
	
  Machinery,
  Equipment and Modules

  	
   

  	
  4.2. The Seller shall deliver the machinery,
  equipment and modules according to DIN / ISO Standards and as specified with
  Appendix 1 and 4.

  
	
   

  	
   

  	
   

  
	
  Documentation

  	
   

  	
  4.3. The Seller shall deliver the documentation
  according with the European and U.S. GMP Regulations and Standards.

  

 5

 

	
  Laws, Regulations and Standards

  	
   

  	
  4.4. The Seller and the Purchaser shall comply with
  all Laws, Regulations and Standards in connection with the performance of
  their respective obligations under the Contract. 

   

  The Purchaser shall provide reasonable assistance to
  Seller in ascertaining the contents of Laws, Regulations and Standards in the
  country where the Site is located to the extent that such Laws, Regulations
  and Standards affect the Seller’s performance of the Contract. The Purchaser
  shall further inform the Seller of any changes in such Laws, Regulations and
  Standards. 

   

  Changes in Laws and Regulations and in their
  generally accepted interpretation or application occurring after signature of
  the Contract Document shall be treated in accordance with Clause 8.

  
	
   

  	
   

  	
   

  
	
  Training

  	
   

  	
  4.5. Seller shall provide training to Purchaser’s
  personnel as specified with Appendix 5.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  5. Purchaser’s Obligations

  
	
   

  	
   

  	
   

  
	
  Site

  	
   

  	
  5.1. The Purchaser shall provide the Seller free
  access on Site in order to enable the Seller to perform the Scope of Supply
  in accordance with the Schedule of Work as attached hereto with Appendix 3 

   

  The Purchaser’s obligations concerning the Scope of
  Supply on Site is specified in the Contract as well as with Appendix 1. 

   

  The Purchaser shall ensure that the working
  conditions on Site satisfy local Laws and Regulations. The Purchaser shall
  prior to the start of Seller’s execution of the Scope of Supply on Site
  notify the Seller of the safety regulations in force on Site.

  
	
   

  	
   

  	
   

  
	
  Support

  	
   

  	
  5.2. The Purchaser shall provide necessary support
  and sign such applications and documents as may be necessary for the Seller
  and it’s Subcontractor to obtain from Government Authorities those licenses,
  permits and rights required to fulfil it’s obligation under this Contract.

  
	
   

  	
   

  	
   

  
	
  Procurement
  by Purchaser

  	
   

  	
  5.3. The Purchaser shall be responsible to provide
  all equipment and services, excluded from the Seller’s Scope of Supply, in
  accordance with the Schedule of Work and with the same quality as specified
  within this Contract. 

   

  Any delay in time and / or variation in quantity and
  / or quality of the provided equipment and services on Site may cause delays
  in the performance of the execution of the Seller. Upon Seller’s request the
  Purchaser shall give to the Seller written notice about the expected delays
  in detail in order to determine time to be added to the Time of Completion.
  Once this period has been determined the Schedule of Work shall be adjusted
  accordingly.

  

 6

 

	
  Taxes, Duties

  	
   

  	
  5.4. Purchaser undertakes to pay in addition to the
  price all those customs, duties, levies, fees and taxes of any kind falling
  due outside the Federal Republic of Germany in connection with this Contract
  as a result of the sale and supply of equipment and parts and/or sale and
  performance of services. In case the Seller is subject to taxation and such
  other charges, Purchaser undertakes to reimburse the corresponding amounts to
  the Seller in addition to the price as per Clause 9 of this Contract. Such
  reimbursement shall be effected sufficiently in advance to allow the Seller
  to correctly and timely settle these payments. The foregoing shall apply to
  all customs, duties, levies, fees and taxes of any kind which will be levied
  from the Seller, from the Seller’s personnel active in connection with this
  Contract from the Seller’s foreign Subcontractor from the Seller’s Subcontractor’s
  personnel active in connection with this Contract.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  If the Seller’s supplies as specified in the present
  Contract or any of his services rendered are subject to VAT in the country of
  destination, the Purchaser shall pay VAT in the Seller’s name directly
  complying with any formalities required by the local fiscal authorities.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  Upon request of Seller, the Purchaser will apply for
  the “Reverse Charge Method” for the Dutch VAT and therefore, the Purchaser
  will execute in due time all necessary VAT forms and declarations for the
  relevant tax authorities.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  6. Schedule of Work, Time of Delivery,
  Liquidated Damages

  
	
   

  	
   

  	
   

  
	
  Schedule
  of Work

  	
   

  	
  6.1. The Seller shall perform the Scope of Supply in
  accordance with the Schedule of Work as attached hereto with Appendix 3
  covering each phase of the execution of the Scope of Supply including
  delivery of all equipment and materials on Site. The Seller reserves the
  right to deviate from and/or modify the Schedule of Work (for reason of due
  performance under this Contract. The Seller shall notify Purchaser
  immediately thereof in writing.

  
	
   

  	
   

  	
   

  
	
  Time of
  Delivery

  	
   

  	
  6.2. Time of delivery, i.e. completion of Seller’s
  Scope of Supply, as per Appendix 3, shall be within sixteen (16) months after
  commencement of the Contract as set forth in Clause 22.12. The Seller’s
  compliance with delivery time is contingent upon the Purchaser’s proper
  fulfilment of all of his obligations.

  
	
   

  	
   

  	
   

  
	
  Default
  of Delivery

  	
   

  	
  6.3. The Seller is deemed to be in default to
  deliver in time if any piece of machinery; equipment and modules is not ready
  for dispatch at the time specified, provided this will hinder timely
  performance of erection and/or commissioning.

  
	
   

  	
   

  	
   

  
	
  Liquidated
  Damages for Delay

  	
   

  	
  6.4 If the Seller’s default in terms of Sub-Clause
  6.3 causes a delay in the commencement of Mechanical Completion, the Seller
  shall pay liquidated damages as follows:

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  For each calendar week of delay in delivery 0.5% of
  the value of the late consignment shall become due; the aggregate of liquidated
  damages shall however not exceed five (5) percent (%) of the total value
  of the equipment and modules as per Price Break Down attached to this
  Contract.

  

 7

 

	
  

  	
   

  	
  Liquidated Damages shall not apply in case the
  Operations Qualification (OQ) has been completed according to the contractual
  project time schedule (Appendix 3)

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  In the event that any supply (equipment and / or
  services) procured by the Purchaser is delayed and causes delays in the
  execution of the Scope of Supply for the Seller, the time of delay, to be
  determined by both parties, will be added on top of the Time of Completion as
  stipulated with Appendix 3; the Schedule of Work shall be adjusted
  accordingly.

  
	
   

  	
   

  	
   

  
	
  Due
  Date for Liquidated Damages

  	
   

  	
  6.5. Liquidated damages for delay under Sub-Clause
  6.4 shall become due at the Purchaser’s demand, but not before the Scope of
  Supply has been taken over or the Contract has been terminated in accordance
  with Clause 15.

  
	
   

  	
   

  	
   

  
	
  Extension
  of Time

  	
   

  	
  6.6. The Seller shall be entitled to a reasonable
  extension of the Time for Completion if he is delayed by:

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  a. failure by the Purchaser to perform
  correctly and in time any of his obligations under the Contract, regardless
  of the reason for such failure,

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  b. actions or omissions by any Subcontractor
  or person employed by the Purchaser,

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  c. any physical conditions (other than
  climatic conditions) or artificial obstructions that the Seller encounters on
  the Site, which could not reasonably have been foreseen by the Seller on the
  basis of data provided by the Purchaser or otherwise readily available or
  from a visual inspection of the Site,

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  d. an approved variation in accordance with
  Clause 8,

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  e. any damage caused by the Purchaser’s Risks,
  or

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  f. any circumstance which constitutes Force
  Majeure.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  6.7. In order to avail himself of his right to an
  extension of time the Seller must, however, notify the Purchaser without
  delay after the time when the Seller becomes aware of or should have realised
  the need for an extension. The notice shall state the reason for the
  extension and, if possible, the length of the extension.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  7. Representatives, Work
  on Site

  
	
   

  	
   

  	
   

  
	
  Project
  Managers, Site Representatives

  	
   

  	
  7.1. The Seller and the Purchaser shall each appoint
  a Project Manager and a Site Representative. In the event that the
  representatives are not named in the Contract, each party shall notify the
  other of the identity of his Project Manager no later than seven
  (7) calendar days after the Commencement Date and of the identity of his
  Site Representative prior to the start of the Seller’s execution of the Scope
  of Supply on Site.

  

 

 8

 

	
  Access to the Site

  	
   

  	
  7.2. The Purchaser shall, on prior notice from the
  Seller, provide access to the Site as and when required by the Seller in
  order to allow him to execute the Scope of Supply.

  
	
   

  	
   

  	
   

  
	
  Purchaser’s
  Obligations

  	
   

  	
  7.3. The Purchaser’s obligations concerning the
  Scope of Supply on Site are specified with Appendix 1.

   

  The Purchaser shall ensure that the working
  conditions on the Site satisfy Laws and Regulations. The Purchaser shall
  prior to the start of the execution of Seller’s Scope of Supply on Site
  notify Seller of the safety regulations in force on Site.

  
	
   

  	
   

  	
   

  
	
  Observance
  of Safety Regulations and Local Laws and Regulations

  	
   

  	
  7.4. The Seller shall ensure that his personnel
  adheres to the safety regulations in force on Site. This shall not affect the
  Purchaser’s obligations under Sub-Clause 7.3. The Purchaser may deny access
  to the Site to any member of the Seller’s personnel who seriously or
  repeatedly fails to observe the safety regulations.

  
	
   

  	
   

  	
   

  
	
  Surplus
  Materials

  	
   

  	
  7.5. Any materials supplied by one party which are
  not consumed in the performance of or incorporated into the Scope of Supply
  shall remain the property of that party. The Seller shall at the Purchaser’s
  request remove from the Site any surplus materials belonging to the Seller.

  
	
   

  	
   

  	
   

  
	
  The
  Seller’s Additional Cost and Expense

  	
   

  	
  7.6. The Seller shall be entitled for compensation
  by the Purchaser as hereinafter specified for additional cost and expenses,
  which the Seller reasonably incurs due to any of the circumstances referred
  to in Sub-Clause 6.6.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  The compensation shall cover: 

   

  -waiting time and time for extra journeys,

   

  -additional material, work, including work to
  remove, secure and set up erection equipment, 

   

  -costs incurred by the Seller in having to keep his
  equipment on the Site longer than foreseen,

   

  -additional costs for travel, board and lodging for
  the Seller’s personnel, and 

   

  -other costs which Seller can show he has incurred
  due to the changed circumstances of the Scope of Supply.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  Where the Seller’s performance of the Scope of
  Supply on Site is affected by Force Majeure the Seller shall be entitled for
  compensation from the Purchaser for any extra costs for demobilization of
  personnel and equipment and for safeguarding of items and materials provided
  for inclusion in the Scope of Supply and related equipment. Any additional
  Cost and Expense caused by a delay or requested by Seller is subject to a
  mutual agreement within five (5) working days after the delay has been
  recognized.

  

 

 9

 

	
  

  	
   

  	
  8. Variations

  
	
   

  	
   

  	
   

  
	
  The
  Seller’s Duty to carry Out Variations

  	
   

  	
  8.1. The Seller shall be obliged to carry out variations
  as the Purchaser requires in the agreed scope, design or manner of execution
  of the Scope of Supply.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  The Seller shall further carry out variations which
  become necessary due to changes in Laws, Regulations and Standards which
  apply to the Scope of Supply and in the generally accepted interpretation or
  application thereof. This obligation shall apply in respect of all amendments
  which come into effect after the commencement of the Contract and before the
  date of Taking Over of the Scope of Supply.

  
	
   

  	
   

  	
   

  
	
  Variations
  Suggested by the Seller

  	
   

  	
  8.2. The Seller shall inform the Purchaser of
  possible Variations, which the Seller considers to be in the interest of the
  Purchaser. The Seller shall further inform the Purchaser of any changes
  occurring in standards and norms, which, according to the Contract, shall be
  observed in the performance of the Scope of Supply.

  
	
   

  	
   

  	
   

  
	
  Amendments
  of Terms of the Contract

  	
   

  	
  8.3. In case of variations the Contract Price, the
  Time of Completion and other terms of the Contract shall be amended to
  reasonably reflect the consequences of the variation. The Seller is not
  obliged to carry out Variations demanded by Purchaser if the Parties have not
  agreed about price increases, extension of time and technical practicability
  caused by such Variations.

  
	
   

  	
   

  	
   

  
	
  Purchaser’s
  Request for a Variation

  	
   

  	
  8.4. The Purchaser shall give notice to the Seller
  of his request for a Variation under Sub-Clause 8.1. The notice shall contain
  a detailed description of the Variation.

  
	
   

  	
   

  	
   

  
	
  Notice
  regarding Terms for a Variation

  	
   

  	
  8.5. The Seller shall, without undue delay after he
  has received the Purchaser’s request referred to in Sub-Clause 8.4, notify
  the Purchaser whether it is possible to carry out the Variation and, if so,
  specify the manner of execution and the effects of the Variation on the
  Contract Price, the Time Schedule and other terms of the Contract.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  The Seller shall also give notice as referred to in
  the first paragraph when he becomes aware of the need for a Variation under
  Sub-Clause 8.1.

  
	
   

  	
   

  	
   

  
	
  The
  Seller’s Costs for Examining a Variation

  	
   

  	
  8.6. The Purchaser shall reimburse any costs
  incurred by the Seller in examining the consequences of a Variation requested
  by the Purchaser. Prior to start any examination of consequences for
  Variation the Seller shall submit a proposal stating the cost and time impact
  to the Purchaser, which is subject to approval by Purchaser.

  

 10

 

	
  

  	
   

  	
  9. Contract Price and Terms of Payment

  
	
   

  	
   

  	
   

  
	
  Contract
  Price

  	
   

  	
  9.1. The Contract Price shall be:

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  EUR 22.570.000,-

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  (in words: EUR twenty two million and five hundred
  seventy thousand)

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  9.2. The Contract Price of the machinery, equipment
  and modules is to be understood for delivery Free on Site / CIP LEIDEN,
  according to INCOTERMS 2000, including proper packing,

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  The above-listed Contract Prices is net, i.e. value
  added tax, if levied for any of Seller’s deliveries and services shall be
  added thereto.

  
	
   

  	
   

  	
   

  
	
  Terms
  of Payment

  	
   

  	
  9.3. The Contract Prices as set out in Clause 9.1
  shall be payable as follows:

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  9.3.1 30% of the
  Contract Price (i.e. EUR 6.771.000) as down payment is due immediately after
  signing the Contract against the Seller’s presentation of a commercial
  invoice

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  9.3.2 30% of the
  Contract Price (i.e. EUR 6.771.000) after approval of URS’s of Main
  Equipment, as specified with Appendix 7, against down payment invoice due
  within 30 days after invoices issue date.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  9.3.3 15% of the
  Contract Price (i.e. EUR 3.385.500) after completion of modular steel
  structures of the prefabricated modules against down payment invoice due
  within 30 days after invoices issue date.

  
	
   

  	
   

  	
  9.3.4 5% of the
  Contract Price (i.e. EUR 1.128.500) after completion of placing the modules
  in place on Site against down payment invoice due within 30 days after
  invoices issue date.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  9.3.5 10% of the
  Contract Price (i.e. EUR 2.257.000) after Mechanical Completion and down
  payment invoice due within 30 days after invoices issue date.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  9.3.6 10% of the
  Contract Price (i.e. EUR 2.257.000) after Completion of the OQ (Operation
  Qualification) and Final Acceptance Certificate as per Article 11.5 and
  final invoice due within 30 days after invoices issue date.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  All invoicing from Seller to Purchaser and all
  payments from Purchaser to Seller are subject to the “Reverse Charge Method”
  as requested by the Dutch Laws and Regulations.

  

 

 11

 

 

	
  Performance Guarantee

  	
   

  	
  9.4. Only with collection of the last installment
  the Seller will submit a Contract Performance Guarantee, issued by a bank,
  for the amount of five (5) percent (%) of the Contract Price as per
  Sub-Clause 9.3

  
	
   

  	
   

  	
   

  
	
  Seller’s Right to Suspend Performance

  	
   

  	
  9.5. If the Purchaser fails to pay on time, the
  Seller shall also be entitled to suspend performance of the Contract in whole
  or in part. The Seller shall give the Purchaser seven (7) days’ notice
  of such suspension. When Seller receives payment, including interest, he
  shall be obliged to resume performance of the Contract, and the provisions of
  Sub-Clause 6.8 through shall apply.

  
	
   

  	
   

  	
   

  
	
  Interest on Late Payment

  	
   

  	
  9.6. If the Purchaser fails to pay on time, the
  Seller shall be entitled to receive interest from the due date at the rate as
  specified in the Contract, or if no rate is specified at a rate which is five
  (5) percentage (%) points above the rate of the main refinancing facility
  of the European Central Bank in force on the due date of payment.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  10. Packing and
  Shipment

  
	
   

  	
   

  	
   

  
	
  Packing

  	
   

  	
  10.1. Packing and preservation, if required, shall
  be made to a reasonable extent with regard to proper handling during
  transport, loading and warehousing at the destination, i.e. in closed
  rooms/halls each according to the Seller’s instructions. If the packing has
  been opened or damaged and/or preservation has been damaged the Purchaser
  shall immediately arrange for a proper protection of the goods and inform the
  Seller in writing accordingly; in such case Purchaser shall either replace
  the packing or safely warehouse the goods in coordination with Seller.

  
	
   

  	
   

  	
   

  
	
  Specifications

  	
   

  	
  10.2. About two (2) weeks prior to date of
  shipment the Seller shall inform the Purchaser about packing specifications,
  giving him approximate details on dimensions and weights of the supplies. In
  due time before shipment will be effected the forwarding agent assigned by
  the Purchaser shall contact the Seller for clarification of transport
  details, and the Seller shall upon request provide all information for
  shipment and transport.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  11. Inspections and Mechanical Completion

  
	
   

  	
   

  	
   

  
	
  Purchaser’s Right to Inspect

  	
   

  	
  11.1. The Purchaser shall be entitled to inspect any
  part of the Scope of Supply at the Seller’s and Subcontractor’s premises and
  on Site. The Purchaser shall give Seller seven (7) calendar days prior
  notice of such inspection. The Seller shall provide the documents and
  information and give the assistance reasonably needed by the Purchaser to
  carry out the inspection.

  
	
   

  	
   

  	
   

  
	
  Cost

  	
   

  	
  11.2. The Seller shall bear the cost for the
  inspection under Sub Clause 11.1 except that cost for the Purchaser’s
  Representative. Notwithstanding the foregoing, the Purchaser shall bear the
  cost for any test required to be carry out by Laws and Regulations in the
  country where the Site is located.

  

 12

 

	
  Notice

  	
   

  	
  11.3. The Seller shall in writing inform the
  Purchaser fourteen (14) calendar days prior to the expected date of Mechanical
  Completion.

  
	
   

  	
   

  	
   

  
	
  Notice of Mechanical Completion, Certificate of
  Mechanical Completion

  	
   

  	
  11.4. After the Seller has given notice for
  Mechanical Completion the parties shall jointly inspect the Plant to
  ascertain that they are complete and ready for Installation Qualification
  (IQ). The Purchaser shall notify the Seller of any work, which, in the
  opinion of the Purchaser, needs to be performed or corrected before the start
  of Installation Qualification (IQ). Purchaser and the Seller shall jointly
  establish the Certificate of Mechanical Completion.

  
	
   

  	
   

  	
   

  
	
  Final Acceptance Certificate

  	
   

  	
  11.5. Upon successful Operation Qualification (OQ),
  documented with the Final Acceptance Certificate, signed by both Parties, the
  Scope of Supply will be considered as accepted and the requirements in
  respect to the performance of the Contract are fulfilled. Any defect which
  may be pending shall be listed. Defects not impairing correct Plant operation
  shall not hinder the acceptance, but shall be specified in the Final Acceptance
  Certificate.

  
	
   

  	
   

  	
   

  
	
  Taking Over

  	
   

  	
  11.6. The Purchaser shall be deemed to have taken
  over the Plant at the time when the Parties have signed the Final Acceptance
  Certificate. Without any mutual written consensus the Purchaser is not
  entitled to take the Scope of Supply or parts of it into operation or
  otherwise use or dispose the Scope of Supply before the Certificate of Final
  Acceptance has been issued, otherwise the Plant shall be deemed as accepted.

  
	
   

  	
   

  	
   

  
	
  Termination due to non acceptable performance

  	
   

  	
  11.7. If it will not be possible to definitely
  eliminate the defects, and if the Plant is unable to produce in a technically
  reasonable manner and cannot be expected to do so in future for reasons
  solely attributed to Seller, the Purchaser shall be entitled to terminate the
  Contract and to rescind the Scope of Supply to the extent they cannot be
  reasonable used by Purchaser, unless otherwise agreed by the Parties.

  
	
   

  	
   

  	
   

  
	
  Reimbursement

  	
   

  	
  11.8. In case the Purchaser cancels the Contract,
  the Seller shall, reimburse the Purchaser all payments made up to that date.
  The Seller shall have the right to concurrently dismount and take back the
  delivered machinery, equipment and modules at his own cost.

  
	
   

  	
   

  	
   

  
	
  Unjustified notice

  	
   

  	
  11.9. If the Purchaser gives notice of a defect and
  no defect for which the seller is liable, the Seller is entitled to
  compensation for the cost occurred as a result of the notice by Purchaser.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  12. Passing of Risk, Liability, Insurance

  
	
   

  	
   

  	
   

  
	
  Incoterms 2000

  	
   

  	
  12.1. The risk of damage or of loss of the Seller’s
  scope of supply shall pass to Purchaser upon arrival on Site -CIP Leiden-
  (INCOTERMS 2000).

  
	
   

  	
   

  	
   

  
	
  Retention of Title

  	
   

  	
  12.2. The Seller reserves the title to his supplies
  until having received all payments resulting from or in connection with this
  Contract.

  
	
   

  	
   

  	
   

  
	
  Site prerequisites

  	
   

  	
  12.3. At the erection on Site the Purchaser shall
  provide appropriate storage, including attendance and custody of the
  machinery and equipment, as well as personnel and equipment for unloading and
  transportation on the Site, free of charge.

  

 

 13

 

	
  Erection and All Risk

  	
   

  	
  12.4. The Purchaser shall take out a regular
  erection all risk insurance and an adequate general liability insurance
  covering damages caused by acts and omissions of his personnel, and he shall
  provide the Seller with a copy of the certificate of insurance if so
  requested.

  
	
   

  	
   

  	
   

  
	
  aCoverage

  	
   

  	
  12.5. Within the scope and amount of Purchaser’s
  coverage under such Insurances he shall be liable for all damages, either
  direct damage to property or personal injury, if the damage was caused by the
  fault and negligence of himself or his personnel.

  
	
   

  	
   

  	
   

  
	
  Insurance by Seller

  	
   

  	
  12.6. The Seller shall provide and maintain a
  General Third Party Liability Insurance, whereas the Seller, its
  Subcontractors and personnel are considered as Third Parties.

  
	
   

  	
   

  	
   

  
	
  Insurance Claim

  	
   

  	
  12.7. When any incident occurs for which cover is
  granted under one of the parties’ insurance policies, the other party shall
  notify that party without undue delay, enclosing a description of the
  incident giving rise to the insurance claim. When the claim is handled by the
  party whose insurance policy covers, the claim, the other party shall provide
  him with reasonable assistance, without claiming compensation.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  13. Defects, Warranty

  
	
   

  	
   

  	
   

  
	
  Warranty

  	
   

  	
  13.1. The Seller warrants to the Purchaser that the
  machinery, equipment and modules to be supplied pursuant to Appendix 1 of
  this Contract shall at the time of passing of risk be free from defects in design,
  material and workmanship and subject to the generally acknowledged state of
  the art. The Seller further warrants that his documentation material as per
  Appendix 2 to this Contract will be free from any error.

  
	
   

  	
   

  	
   

  
	
  Seller’s Obligation to Remedy Defects

  	
   

  	
  13.2. The Seller shall, in accordance with this
  Clause 13, remedy any defects in the Scope of Supply which are due to faulty
  design, materials or workmanship. A deviation from a performance undertaking
  or guarantee, for which the Purchaser is entitled to liquidated damage sunder
  Sub-Clause 6.5 shall not in itself be considered a defect under this Clause
  13.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  The Seller’s liability does not cover defects which
  are due to errors or omissions in documentation, materials or work which has
  been supplied or performed by the Purchaser.

   

  The Seller shall be liable for all defects due to
  incorrect design. The Seller shall not, however, be liable for defects which
  are due to a design which has been requested by the Purchaser after signature
  of the Contract, 

   

  provided that the Seller disclaims liability by
  notice to the Purchaser before manufacture or, where applicable, the
  execution of the Scope of Supply on Site has started.

  

 

 14

 

	
  Warranty Period

  	
   

  	
  13.3. The warranty shall expire twelve (12) months
  after the issue of the Certificate of Mechanical Completion according to
  Sub-Clause 11.5, irrespective of the number of shifts run, at the latest
  twenty six (26) months after Commencement Day.

  
	
   

  	
   

  	
   

  
	
  Notice of Defects, Defects for which The Seller
  is not Liable for

  	
   

  	
  13.4. Any defect which Purchaser immediately
  notifies to the Seller in writing or by facsimile within the warranty period
  shall be remedied by the Seller free of charge to Purchaser. Such immediate
  notification of the Purchaser shall include a description as detailed as possible
  of the scope, alleged cause and effects of any such defect. Defects will not
  be subject to this warranty, if they are due to improper storage, improper
  operation and/or maintenance by Purchaser’s personnel, or unsuitable supplies
  by Purchaser, e.g. of raw materials. The warranty does not apply to ordinary
  wearing parts, as long as these have been subject to regular use, normal for
  operation and plant. 

   

  A defective part of the Plant which has been
  replaced shall be put at Seller’s disposal, free of charge, and become his
  property.

  
	
   

  	
   

  	
   

  
	
  Replacement, Replaced Parts

  	
   

  	
  13.5. The Seller’s obligations under the above
  stipulated warranties shall be limited to replacement of equipment or parts
  determined to be defective or to their repair if possible, and to re-performance
  of engineering services, as the case may be. Costs for repair, replacement or
  re-performance, including transport to the Site shall be at the Seller’s
  charge. Import duties or public charges, if any, shall be subject to
  Sub-Clause 5.3. Purchaser undertakes to give the Seller its best support in
  any repair of the Scope of Supply by making available his own personnel,
  material and tools free of charge. A defective part of the Plant which has
  been replaced shall be put at the Seller’s disposal, free of charge, and
  become his property, if so requested. The Seller shall be entitled to take
  from Purchaser’s stock any spare parts he may need for repair, but shall
  immediately replace the removed parts free of cost to Purchaser.

  
	
   

  	
   

  	
   

  
	
  Purchaser’s Right to correct Defects

  	
   

  	
  13.6. Purchaser shall be entitled to correct the
  defect by himself or through third parties and charge the Seller with the
  reasonable costs directly related to such corrective actions only in case the
  Seller does not commence correction of the defect within reasonable time or
  refuses correction in writing.

  
	
   

  	
   

  	
   

  
	
  Limitation of Warranty

  	
   

  	
  13.7. The foregoing warranty is in lieu of any other
  warranties. The Seller makes no warranty for merchantability of the products
  or fitness for a particular purpose, whether neither implied nor expressed,
  except as set out in this Contract.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  14. Safety Standards

  
	
   

  	
   

  	
   

  
	
  Safety Standards

  	
   

  	
  In addition to the safety standards as referred to
  in Sub-Clause 7.4 and other technical standards as referred to in this
  Contract, the Seller shall take all reasonable care of the assigned personnel
  for site work to comply with all in-house safety standards of Purchaser and
  other pertinent safety regulations; the Seller has to be notified by
  Purchaser about these safety standards and regulations well in time.
  Purchaser may request the Seller to replace personnel engaged by him for the
  performance of the Scope of Supply on Site in case of reasonable cause, in
  particular in case of failure to comply with safety regulations.

  

 

 15

 

	
  

  	
   

  	
  15. Termination

  
	
   

  	
   

  	
   

  
	
  Purchaser’s Right to Terminate

  	
   

  	
  15.1. The Purchaser is entitled by notice to the
  Seller to terminate the Contract for his convenience

  
	
   

  	
   

  	
   

  
	
  Protocol

  	
   

  	
  15.2. Within seven (7) calendar days after the
  notice under Sub-Clause 15.1, the parties shall conclude a protocol stating
  the percentage of the Scope of Supply which has been completed. If the
  parties are unable to agree each party shall state the percentage he
  considers to have been completed. Each party may thereafter by notice to the
  other party refer the question to be settled by an independent expert.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  If the parties fail to agree on the choice of the
  expert, Purchaser or the Seller may request the nomination of such expert by
  the International Centre for Expertise of the International Chamber of
  Commerce. The parties shall give a copy of such request to each other.

  
	
   

  	
   

  	
   

  
	
  Procedure of Expert Opinion

  	
   

  	
  15.3. Each party shall, within seven
  (7) calendar days after the appointment of the expert, submit to the
  Expert the documents he wishes to rely on, with a copy to the other party.
  Each party may thereafter, within seven (7) calendar days after it
  received the other party’s documents, submit such further documents as he
  wishes to rely on.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  In the event that either party challenges the
  jurisdiction of the Expert to resolve any issue which is referred to him by
  one of the parties, both parties agree that the Expert shall have
  jurisdiction to determine the issue of his own jurisdiction.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  The Expert shall inform the parties in writing of
  his decision, with a brief description of the reasons, no later than
  twenty-eight (28) calendar days after he received the last documents from the
  parties.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  The Expert shall in his decision determine the
  sharing of his fee and costs between the parties. Each party shall bear his
  own costs.

  
	
   

  	
   

  	
   

  
	
  Payment at Termination

  	
   

  	
  15.4. Following termination under Sub-Clause
  15.1, the Purchaser shall pay to the Seller:

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
  a) the unpaid balance due to the Seller for the
  part of the Plant that has already been performed,

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
  b) all costs incurred by the Seller and his
  Subcontractors in connection with materials ordered prior to receipt of the
  notice of termination , and compensation for the Scope of Supply performed on
  such materials prior to the said date, to the extent that such costs are not
  covered by payment under Sub-Clause 15.4.a),

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
  c) all termination charges and administration
  costs reasonably incurred by the Seller in connection with the termination,
  and

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
  d) the Seller’s and his Subcontractors other
  expenses directly attributable to an orderly close-out of the Contract.

  

 

 16

 

	
  Termination Fee

  	
   

  	
  15.5. In addition to the amounts referred to in
  Sub-Clause 15.4, the Purchaser shall pay a termination fee equal to six
  (6) percent (%) of the part of the Contract Price which is not paid at
  the date of cancellation. The Purchaser shall only be entitled to deduct from
  the termination fee such claims as have been notified to the Seller prior to
  the date of termination and have been accepted by the Seller.

  
	
   

  	
   

  	
   

  
	
  Seller’s Right for Termination

  	
   

  	
  15.6. In the event that the Purchaser shall be in
  default under this Contract and should fail, neglect or refuse to remedy such
  default within hundred and twenty (120) calendar days from the date of
  receipt by the Purchaser of the Seller’s written notice of such default, or
  if such default is one, which cannot reasonably be remedied within hundred
  and twenty (120) calendar days, and if the Purchaser does not within such
  period commence the necessary remedial action required and / or continue with
  due diligence until necessary remedial action has been taken, and in such
  event, the Seller shall have the right to terminate the Contract by giving
  written notice to the Seller specifying the reasons for termination, and the
  date upon which such termination becomes effective. Upon such date, the
  Seller shall immediately discontinue the execution of the Scope of Supply and
  shall make every reasonable effort to obtain cancellation of all existing
  commitments, and shall thereafter do only such work as the Parties may agree
  is necessary to preserve and protect the Scope of Supply already in progress
  and to protect the supplies in transit.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  Upon termination of the Contract by Seller in
  accordance with this Article, the Purchaser shall pay to the Seller:

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
  a) Such portion
  of the Contract Price that correspond to portion of the Scope of Supply
  actually carried out by the Seller

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
  b) Any costs reasonably and necessarily
  incurred by the Seller in connection with the termination of the Contract
  (such as cost for protection and / or disposal of the Scope of Supply) which
  have not previously been paid by the Purchaser.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
  c) In no event shall the Purchaser be liable to
  pay any sum, when added to the other sums paid, due or becoming due to the
  Seller under the Contract, that shall exceed ten (10) percent (%) of the
  Contract Price, nor shall the Purchaser be liable for any damage other than
  direct damages.

  
	
   

  	
   

  	
   

  
	
  Seller’s Right to Compensation

  	
   

  	
  15.7. In case of termination in accordance with
  Sub-Clause 15.6, the Seller shall be entitled to compensation for the loss he
  suffers.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  The compensation shall not exceed the sum of the
  Contract Price and any interest for late payment which has accrued at the
  date of termination, reduced by the costs which the Seller can save as a
  result of the termination.

  

 

 17

 

	
  

  	
   

  	
  16. Intellectual
  Property Rights

  
	
   

  	
   

  	
   

  
	
  Equipment, Documentation

  	
   

  	
  16.1. The Seller warrants that the equipment and
  documentation within his scope of supplies and services are free from any
  industrial property rights and other property rights of third parties. The
  foregoing warranty shall not cover the particular use of the equipment by Purchaser
  which may be covered by industrial property rights of third parties for a
  specific production process, process features or combination with other
  equipment. The copyright to the documentation remains with the author.

  
	
   

  	
   

  	
   

  
	
  Computer Software

  	
   

  	
  16.2. The Purchaser shall, unless otherwise
  specified in the Contract, have the right to use computer software included
  in the Plant for the intended operation, and thereby to make the necessary
  changes in the software.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  Unless otherwise specified in the Contract, the
  Seller shall not be obliged to provide the Purchaser with the source code for
  the computer software. In respect of computer software to which a third party owns the copyright the
  Purchaser’s right of use shall be limited to the extent that may follow from
  the Seller’s agreement with that third party. The Seller shall notify the
  Purchaser of such limitations.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  The Purchaser shall be entitled to assign his right
  to use computer software to anyone who acquires the Plant.

  
	
   

  	
   

  	
   

  
	
  Indemnification

  	
   

  	
  16.3. In case
  of a claim of any third party
  brought against Purchaser, Purchaser shall immediately notify the Seller
  thereof. The Seller shall indemnify and hold Purchaser harmless from such
  claim provided the claim is finally awarded to the third party. Purchaser and
  Seller shall agree on measures to be taken for the defence against such
  claim. If possible Seller shall provide for modification or replacement of
  infringing Equipment parts by equivalent material to make it non-infringing
  or shall settle the dispute on behalf of the Purchaser by payment of a
  royalty to the claimant.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  17.
  Confidentiality

  
	
   

  	
   

  	
   

  
	
  Prohibition of Unauthorized Use

  	
   

  	
  17.1. Neither party
  may, without the other party’s consent, use or disclose to a third party any
  technical or commercial information originating from the other party, which
  that party has stated to be confidential or which is otherwise of a clearly
  confidential nature, unless such information has entered the public domain
  through no fault of the receiving party.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  The obligation of confidentiality shall not apply,
  however, to the extent that such use or disclosure is necessary for the
  receiving party in order to perform his obligations under the Contract, or
  for operation, maintenance and inspection of the Plant.

  
	
   

  	
   

  	
   

  
	
  Preventive Measures

  	
   

  	
  17.2. Each
  party shall take measures to prevent information referred to in Sub-Clause
  17.1 from being disclosed to unauthorised persons or otherwise being
  improperly used by employees, consultants, Subcontractor, other contractors
  and others who are given access to such information. A party who is in breach
  of the confidentiality shall compensate the other party for the damage caused
  by such breach.

  

 

 18

 

	
  

  	
   

  	
  18. Force Majeure

  
	
   

  	
   

  	
   

  
	
  Force Majeure

  	
   

  	
  18.1. Force Majeure in terms of this clause shall
  mean any occurrences of extraordinary character unforeseen at the time of
  Contract conclusion and which were and are unavoidable by any precautionary
  measures which can reasonably be expected to be taken in compliance with the
  present state of the art. These includes without limitation Act of God, acts
  of government, industrial disputes, flood, fire, storm, war, riots, civil
  disturbances, strike, lock-out, shortage of material or labour, breakdown of
  machinery.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  18.2. Force Majeure shall not relieve the parties
  from their obligations under this Contract with the exception specified
  below:

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  If the fulfilment of any of one party’s obligations
  is substantially affected or rendered impossible by Force Majeure, this party
  (the aggrieved party) shall not be considered to be in default for the time
  during which as a result of a Force Majeure the aggrieved party
  is prevented or substantially affected to fulfil its obligations and the time
  of fulfilment shall be extended accordingly.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  In case extension of time will exceed six
  (6) months, the non-aggrieved party may cancel the Contract for the
  non-performed part of supplies and services, either in part or completely, if
  the parties cannot achieve agreement on Contract adaptation during a further
  period of three (3) months.

  
	
   

  	
   

  	
   

  
	
  Notice

  	
   

  	
  18.3. The party whose obligation to perform is
  affected by Force Majeure (the aggrieved party) shall inform the other party
  about the occurrence of Force Majeure, the anticipated delay and the end of
  Force Majeure within ten (10) calendar days by facsimile which shall
  without delay be followed by a written confirmation of the occurrence of
  Force Majeure. In case of non-compliance of these obligations, the aggrieved
  party will have no means to invoke Force Majeure.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  19. Limitation of Liability

  
	
   

  	
   

  	
   

  
	
  Limitation of Liability

  	
   

  	
  19.1. Notwithstanding any other provision in this
  Contract to the contrary, neither Party shall be liable to the other Party by
  way of indemnity or otherwise for any indirect or consequential damages
  including loss of anticipated profits, irrespective of whether based on
  Contract, tort (including negligence) or otherwise, except wilful misconduct
  and / or gross negligence.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  19.2. The total limit of liability of the Seller
  whether under or in connection with the Contract or in tort including all
  liability for payment of damages whether liquidated or at large shall be ten
  (10) percent (%) of the Contract Price in aggregate.

  

 

 19

 

	
  

  	
   

  	
  20. Notices and Language

  
	
   

  	
   

  	
   

  
	
  Notices and Language

  	
   

  	
  Whenever under these Contract a party is obliged to
  notify or inform the other party, to make a request or give his consent or
  approval, such communication shall be by means of a written, printed or
  printable communication from a party to the other party which identifies the
  sender and reaches the other party by mail, messenger, facsimile or confirmed
  electronic mail. Such communication shall also be valid when entered in
  minutes from a meeting and signed by both parties.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  English shall be the ruling language of this
  Contract even if versions of the Contract are prepared in different
  languages.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  21. Arbitration, Applicable Law

  
	
   

  	
   

  	
   

  
	
  Amicable Settlement

  	
   

  	
  21.1. The parties shall use their good faith efforts
  to amicably settle any dispute arising out of or in connection with the
  execution and performance of this Contract.

  
	
   

  	
   

  	
   

  
	
  ICC Arbitration

  	
   

  	
  21.2. If no amicable settlement can be reached
  between the parties, all disputes out of or in connection with this Contract
  shall be finally settled by arbitration according to the Rules of
  Conciliation and Arbitration of the International Chamber of Commerce by
  three (3) arbitrators appointed according to said Rules. Venue shall be
  Amsterdam, The Netherlands. The court of arbitration shall decide upon the
  dispute primarily according to the provisions of this Contract and
  secondarily according to the Dutch Law.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  22. Miscellaneous

  
	
   

  	
   

  	
   

  
	
  The Agreement

  	
   

  	
  22.1. This Contract, including its Appendices
  referred to therein, shall constitute the complete agreement between the
  parties. All prior representations, statements, offers and agreements, except
  the approved Basic Engineering Package (Appendix 9) shall be null and void.
  Any modifications and amendments to this Contract are valid only if made in
  writing and signed by both parties. Any notifications to be made to either
  party under this Contract must also be made in written form. The Contract
  constitutes the entire agreement between the parties. Written or oral
  communications and statements from the parties made before or in connection
  with entering into the Contract are only part of the Contract if expressly
  incorporated therein. This Contract may be amended only by written
  instruments signed by both parties.

  
	
   

  	
   

  	
   

  
	
  Invalid Provisions

  	
   

  	
  22.2. In case any individual provisions of this
  Contract should be or become invalid, such invalid provisions shall be
  replaced by valid ones which come closest to the meaning, intentions and
  economic purpose of the invalid Contract provision.

  
	
   

  	
   

  	
   

  
	
  Independent Contractor

  	
   

  	
  22.3. In the performance of the Scope of Supply
  hereunder, the Seller is acting as and independent Contractor, not an agent
  or employee or substitute of the Purchaser.

  
	
   

  	
   

  	
   

  
	
  Seller’s Project Manager

  	
   

  	
  22.4. In the administration of the Contract, the
  Seller is represented by his Project Manager, who may from time to time
  delegate its authority in writing in whole or in part to others of the
  Seller’s organization.

  

 

 20

 

	
  Purchaser’s Project Manager

  	
   

  	
  22.5. In the administration of this Contract, the
  Purchaser is represented by his Project Manager, who has authority to act for
  and on behalf of the Purchaser and who may from time to time delegate his
  authority in writing, in whole or in part, to others.

  
	
   

  	
   

  	
   

  
	
  Assignment

  	
   

  	
  22.6. Purchaser’s rights under this Contract shall
  not be assigned nor shall any lien be created without the Seller’s previous
  written consent. Otherwise any such assignment or lien shall be null and
  void.

  
	
   

  	
   

  	
   

  
	
  Guarantees and Warrantees

  	
   

  	
  22.7. The Seller makes no guarantees or warranties
  and the Parties assume no obligations except those expressly stated herein.

  
	
   

  	
   

  	
   

  
	
  Headings

  	
   

  	
  22.8. The descriptive headings of Articles and
  Sections are inserted solely for convenience of reference and are not
  intended as complete or accurate descriptions of the content of such Clauses
  or Sub-clauses.

  
	
   

  	
   

  	
   

  
	
  Approval, Consent

  	
   

  	
  22.9. Whenever a provision of this Contract requires
  an approval or consent by a Party to this Contract and notification of such
  approval or consent is not delivered within the applicable time limit, then,
  unless otherwise specified, the Party whose approval or consent is required
  shall be conclusively deemed to have withheld its approval or consent. The
  Purchaser shall review and approve submitted documents prepared by Seller
  within five (5) calendar days after receipt of those documents. In case
  changes are necessary, Seller will incorporate and prepare revised documents
  which will be submitted to Purchaser’s final approval. Only one (1) revision
  cycle per document approved by purchaser is included; all further revisions
  are subject to Variation of the Scope of Supply, as specified with Clause 8.

  
	
   

  	
   

  	
   

  
	
  Conflict Contract — Appendices

  	
   

  	
  22.10. In the event of any conflict between this
  Contract and any Appendix, this Contract shall prevail.

  
	
   

  	
   

  	
   

  
	
  Waiver

  	
   

  	
  22.11. Waiver of any breach or failure to exercise
  any right hereunder, or failure to enforce any of the terms and conditions of
  the Contract shall not in any way affect, prejudice, limit or waive the right
  of the Parties hereto hereafter to require strict compliance with every term
  and condition thereof.

  
	
   

  	
   

  	
   

  
	
  Commencement Date

  	
   

  	
  22.12. This Contract shall come into force on the
  date, on which the last of the following event occurs :

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  - if the Contract including all Appendices to this
  Contract are signed by both parties

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  - if the down payment according to Clause 9 has been
  paid in full and credited to Seller’s account

  
	
   

  	
   

  	
   

  
	
  Priority of Contract Documents

  	
   

  	
  22.13. If the Contract contains conflicting provisions,
  the provisions in this Contract shall have priority over provisions in the
  Appendices and the Appendices shall have priority over the offer made by
  Seller. The approved basic design has priority over the offer made by Seller
  and over the tender of Purchaser.

  

 

 21
 

 

 

IN WITNESS WHEREOF, the
duly authorised representatives of the parties have executed this Agreement on this August 27, 2005.

 

	
  Crucell HOLLAND B.V.

  	
   

  	
  Pharmaplan International GmbH

  
	
   

  	
   

  	
   

  
	
  /s/ Ronald Brus

  	
   

  	
   

  	
  /s/ Klaus Lesker

  	
   

  
	
   

  	
   

  	
   

  
	
  Name: Dr. Ronald Brus

  	
   

  	
  Name: Dr. Klaus Lesker

  
	
   

  	
   

  	
   

  
	
  Position: CEO

  	
   

  	
  Position: CEO

  
					

 

	
  /s/ Leonard Kruimer

  	
   

  	
   

  	
  /s/: I.V. Volker Kenschke

  	
   

  
	
   

  	
   

  	
   

  
	
  Name: Leonard Kruimer

  	
   

  	
  Name: I.V. Volker Kenschke

  
	
   

  	
   

  	
   

  
	
  Position: CFO

  	
   

  	
  Position: Project Manager

  

 

	
  /s/ Aron F. Gaiser

  	
   

  	
   

  	
  /s/ I.A. Thomas Meyer

  	
   

  
	
   

  	
   

  	
   

  
	
  Name: Aron F. Gaiser

  	
   

  	
  Name: I.A. Thomas Meyer

  
	
   

  	
   

  	
   

  
	
  Position: Project Manager

  	
   

  	
  Position: Sales Engineer

  

 

 22

 

	
  

  	
   

  	
  23. Appendices

  
	
   

  	
   

  	
   

  
	
  Appendix 1

  	
   

  	
  Scope of Supply

  
	
   

  	
   

  	
   

  
	
  Appendix 2

  	
   

  	
  List of deliverable Documents

  
	
   

  	
   

  	
   

  
	
  Appendix 3

  	
   

  	
  Schedule of Work

  
	
   

  	
   

  	
   

  
	
  Appendix 4

  	
   

  	
  Technical Standards and Local Regulations

  
	
   

  	
   

  	
   

  
	
  Appendix 5

  	
   

  	
  Training

  
	
   

  	
   

  	
   

  
	
  Appendix 6

  	
   

  	
  Exclusions

  
	
   

  	
   

  	
   

  
	
  Appendix 7

  	
   

  	
  List of URS’s for Main Equipment

  
	
   

  	
   

  	
   

  
	
  Appendix 8

  	
   

  	
  Organization Chart and CV’s

  
	
   

  	
   

  	
   

  
	
  Appendix 9

  	
   

  	
  Basic Engineering Package according to “Table of
  Contents for Basic Engineering” submitted to Purchaser.

  

 

 23

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00106-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00106-of-00352.parquet"}]]